Long COVID: Symptoms, Causes, and How AI Is Ushering New Hope
Long COVID is a chronic state that can be diagnosed when symptoms or diagnosable conditions persist for at least three months following a SARS-CoV-2 infection. It falls under a broader category known as post-acute sequelae of SARS-CoV-2 infection (PASC) and is recognized as a newly emerging infection-associated chronic condition (IACC). What makes Long COVID particularly […]
Delta4 Leads Training on Big Data Applications in CKD Research at PerMediK Lisbon, March 2025
Continuing its active engagement with the COST Action PerMediK network, Delta4 participated in the 6th Management Committee Meeting and Action Workshop held in Lisbon, Portugal on March 14–15, 2025. Representing Delta4, Lead Software Engineer Matthias Ley led the opening training session titled “Leveraging Big Data for Chronic Kidney Disease Research: Real-World Use-Cases and Data Skills […]
Delta4 At BIO-Europe
Delta4 Reflects on a Milestone BIO-Europe Spring 2025 in Milan Delta4 is pleased to share highlights from this year’s BIO-Europe Spring 2025, held in Milan, Italy—an event that marked our most successful participation to date. Representing Delta4 were Kurt Herpel (CEO) and Klaus Kratochwill (CSO), who spent two fully packed days in one-on-one meetings with […]
Delta4 Secures European Patents for Two Compounds as Candidate Treatments for Focal Segmental Glomerulosclerosis (FSGS)
Vienna, Austria – January 31th, 2025 – Delta4, a leader in AI-driven drug discovery and indication expansion, is proud to announce that it has been granted European patents for two innovative compounds positioned as candidate treatments for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. These patents mark a significant milestone in Delta4’s […]
Generative AI in Pharma: Revolutionizing Drug Discovery for Rare Diseases
The pharmaceutical industry is on the cusp of a revolution. Generative AI, as highlighted in McKinsey’s 2024 report, is transforming how drugs are discovered, developed, and brought to market. By enhancing R&D processes, reducing costs, and accelerating timelines, this technology has the potential to reshape the future of healthcare. At Delta4, we are leveraging big-data-driven […]
Delta4 Featured on PharmaVentures Podcast: AI in Drug Discovery
Delta4’s CEO, Kurt Herpel, and CSO, Klaus Kratochwill, were recently featured on the PharmaVentures podcast, where they discussed how Delta4 is transforming the landscape of drug discovery through AI. This engaging conversation sheds light on the roots of the company and the innovative work happening at Delta4, as well as the potential of AI to […]
The Role of Drug Combination in Modern Medicine: Delta4’s Innovative Approach
The use of multiple active ingredients in medicine is a time-honored practice, with roots stretching back to Traditional Chinese Medicine (TCM) and various formulations in traditional medicine across the world based on the combination of plant and natural substances [24764197, 29799486, 36114271]. Combining multiple active ingredients, also known as drug combinations, is an increasingly important […]
Delta4: A Trusted Partner in EU Horizon Research Projects
Delta4 is proud to announce its participation in two significant EU Horizon research projects: PICKED (Personalized Medicine in Chronic Kidney Disease) and PROMOTE (Prostate Cancer Omics Mediated Intervention). Horizon Europe is the world’s largest research funding program, focusing on advancing health, biomedical research, data science, and AI/ML. With a total budget of nearly EUR 100 […]
Leveraging Multi-Omics Data for Drug Repurposing and Discovery at Delta4
At Delta4, we leverage multi-omics data to identify novel drug repurposing opportunities by uncovering molecular similarities between diseases and existing drugs. This integrative approach holds promise for accelerating the development of effective treatment strategies across rare and complex conditions. What is Omics Data? Omics data refers to comprehensive datasets that capture various types of molecular […]
Delta4 Featured in the Finanz und Wirtschaft (FuW)
Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article sheds light on how our AI-powered platform, Hyper-C, identifies novel therapeutic uses for existing drugs, offering hope for more efficient and effective treatment strategies for a range of complex conditions. […]